STOCK TITAN
  1. Home
  2. Sec-filings
  3. IRMD
  4. [Form 4] IRADIMED CORP Insider Trading Activity

Iradimed (IRMD) CEO and 10% owner Roger Susi discloses Rule 10b5-1 stock sales

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Iradimed Corp’s CEO, president, chairman and 10% owner Roger E. Susi reported insider sales of the company’s common stock. On 12/15/2025, a Rule 10b5-1 trading plan arranged for the sale of 4,269 shares at a weighted average price of $96.68 and 731 shares at a weighted average price of $97.13, both through the Phillip Susi 2008 Dynasty Trust.

After these transactions, the form reports indirect beneficial ownership of 2,292,500 shares by the Phillip Susi 2008 Dynasty Trust, 162,950 shares by the Roger E. Susi Revocable Trust, and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust. The filing notes the trades were executed under a pre-established Rule 10b5-1 trading plan adopted on June 16, 2025, and that beneficial ownership of certain securities is disclaimed except to the extent of pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Susi Roger E.
Role CEO, PRESIDENT, CHAIRMAN
Sold 5,000 shs ($484K)
Type Security Shares Price Value
Sale Common Stock 4,269 $96.68 $413K
Sale Common Stock 731 $97.13 $71K
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 2,293,231 shares (Indirect, By Phillip Susi 2008 Dynasty Trust)
Footnotes (1)
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. This transaction was executed in multiple trades at prices ranging from $96.23 to $96.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $97.03 to $97.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Susi Roger E.
(Last) (First) (Middle)
C/O IRADIMED CORPORATION
12705 INGENUITY DRIVE
(Street)
ORLANDO FL 32826
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
CEO, PRESIDENT, CHAIRMAN
3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/15/2025 S(1) 4,269 D $96.68(2) 2,293,231 I By Phillip Susi 2008 Dynasty Trust
Common Stock 12/15/2025 S(1) 731 D $97.13(3) 2,292,500 I By Phillip Susi 2008 Dynasty Trust
Common Stock 162,950 I By Roger E. Susi Revocable Trust
Common Stock 2,062,500(4) I By Matthew Susi 2008 Dynasty Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.
2. This transaction was executed in multiple trades at prices ranging from $96.23 to $96.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. This transaction was executed in multiple trades at prices ranging from $97.03 to $97.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.
/s/ Roger E. Susi 12/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did IRADIMED CORP (IRMD) report for Roger E. Susi?

The report shows that Roger E. Susi, Iradimed’s CEO, president, chairman and 10% owner, had two sales of common stock on 12/15/2025 through an indirect trust.

How many IRMD shares were sold in the latest insider transactions?

The filing reports that the Phillip Susi 2008 Dynasty Trust sold 4,269 shares of Iradimed common stock at a weighted average price of $96.68 and 731 shares at a weighted average price of $97.13.

Were the IRMD insider sales made under a Rule 10b5-1 trading plan?

Yes. The explanation states that the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

What is Roger E. Susi’s reported indirect beneficial ownership in IRMD after these trades?

After the reported trades, the form lists indirect beneficial ownership of 2,292,500 shares by the Phillip Susi 2008 Dynasty Trust, 162,950 shares by the Roger E. Susi Revocable Trust, and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust.

Does Roger E. Susi disclaim beneficial ownership of any reported IRMD shares?

Yes. The filing notes that the reporting person disclaims beneficial ownership of certain securities except to the extent of his pecuniary interest, and that including these shares does not constitute an admission of beneficial ownership.

How were the sale prices for the IRMD insider trades determined in the report?

The filing explains that each transaction was executed in multiple trades within specified price ranges and that the prices reported, $96.68 and $97.13, are weighted average sale prices.